The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | BEAT-SC: Phase III trial of bevacizumab or placebo with atezolizumab & chemo in extensive-stage SCLC
Melina Elpi Marmarelis, MD, University of Pennsylvania, Philadelphia, PA, discusses the efficacy and safety of combining bevacizumab with atezolizumab and platinum-based chemotherapy in extensive-stage small-cell lung cancer (ES-SCLC) patients from Japan and China. The BEAT-SC trial showed that adding bevacizumab to the regimen significantly increased progression-free survival (PFS) compared to placebo. However, the first interim analysis for overall survival (OS) did not show a significant improvement. The combination was well-tolerated, with similar treatment-related adverse events between groups. Further OS follow-up is ongoing. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock and Other Ownership Interests – Bluebird Bio; Gilead Sciences; Johnson & Johnson; Merck; Pfizer; Portola Pharmaceuticals
Honoraria – AstraZeneca; Blueprint Medicines; Blueprint Medicines; Health Advances (I); Janssen Oncology; Novocure; Takeda; Targeted Oncology; Thermo Fisher Scientific
Consulting or Advisory Role – AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Ikena Oncology
Research Funding – AstraZeneca (Inst); Lilly (Inst); Trizell (Inst)
Travel, Accommodations, Expenses – Boehringer Ingelheim; Novocure
